Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Merck Serono and Domain Therapeutics Announce an Agreement to Develop Drugs for Parkinson's Disease - Merck Serono to Develop Domain Therapeutics' mGluR4 Allosteric Modulators PR Newswire GENEVA...
Brighter Futures in MS - Inspiring Short Film Premieres in Brussels PR Newswire GENEVA and BRUSSELS, January 12, 2011 GENEVA and BRUSSELS, January 12, 2011 /PRNewswire/ -- Merck Serono, a...
Merck Serono and San Raffaele Scientific Institute to Collaborate on Research in Neurodegenerative Diseases PR Newswire GENEVA, December 13, 2010 GENEVA, December 13, 2010 /PRNewswire/ -- Merck...
Merck Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of Multiple Sclerosis - FDA Extends Priority Review period of Cladribine...
Merck Serono: Enrollment Completed for ORACLE MS Study of Cladribine Tablets in Patients at Risk of Developing MS PR Newswire GENEVA, November 17, 2010 GENEVA, November 17, 2010 /PRNewswire/...
Merck Serono: Ready-to-Use Formulation of Recombinant Growth Hormone Saizen Recommended for Approval in Europe - Saizen(R) Solution For Injection Eliminates the Need to Reconstitute Powder for...
Merck Serono Announces Top-Line Results of Long-Term Study of Safinamide as Add-on Treatment to Levodopa in Advanced Parkinson's Disease PR Newswire GENEVA, Switzerland, November 4, 2010 GENEVA...
Merck Serono Sells Théramex to Teva for EUR 265 Million - Acquisition Will Provide Teva With a Strong Platform to Expand its Global Women's Health Business - Merck Serono to Maintain Focus on its...
Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First Clinical Signs of the Disease - Study Met its Primary Endpoint - Risk of Converting...
Merck Serono to Introduce RebiDose(TM), the Rebif(R) Single Use Pre-filled Pen for Treatment of Multiple Sclerosis - RebiDose(TM) has Been Developed With the Goal to Simplify the Rebif(R...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
